Terms: = Thyroid cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
64 results:
1. Correlation between ferroptosis and adriamycin resistance in breast cancer regulated by transferrin receptor and its molecular mechanism.
Yu X; Cheng L; Liu S; Wang M; Zhang H; Wang X; Zhang H; Yang Z; Wu S
FASEB J; 2024 Mar; 38(5):e23550. PubMed ID: 38466338
[TBL] [Abstract] [Full Text] [Related]
2. Contrast-Enhanced Ultrasound and Conventional Ultrasound Characteristics of Breast cancer With Different Molecular Subtypes.
Li X; Zhang J; Zhang G; Liu J; Tang C; Chen K; Chen P; Tan L; Guo Y
Clin Breast Cancer; 2024 Apr; 24(3):204-214. PubMed ID: 38102010
[TBL] [Abstract] [Full Text] [Related]
3. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
4. A pH/H
Cheng P; Cheng L; Han H; Li J; Ma C; Huang H; Zhou J; Feng J; Huang Y; Lv Y; Huang H; Wang Y; Hou L; Chen Y; Li G
Adv Healthc Mater; 2022 Nov; 11(22):e2200971. PubMed ID: 36056927
[TBL] [Abstract] [Full Text] [Related]
5. Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis.
Li H; Liu W; Zhang X; Wu F; Sun D; Wang Z
Biochem Biophys Res Commun; 2021 Dec; 585():111-116. PubMed ID: 34800882
[TBL] [Abstract] [Full Text] [Related]
6. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated thyroid cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract] [Full Text] [Related]
7. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer.
Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Miccoli M; Galdiero MR; Varricchi G; Foddis R; Guglielmi G; Spinelli C; La Motta C; Benvenga S; Antonelli A; Fallahi P
Expert Opin Investig Drugs; 2021 Sep; 30(9):913-921. PubMed ID: 34428101
[TBL] [Abstract] [Full Text] [Related]
8. Surufatinib: First Approval.
Syed YY
Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
[TBL] [Abstract] [Full Text] [Related]
9. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract] [Full Text] [Related]
10. Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/fgfr1 axis.
Jiang J; Lin H; Shi S; Hong Y; Bai X; Cao X
Thorac Cancer; 2020 Nov; 11(11):3181-3192. PubMed ID: 33000910
[TBL] [Abstract] [Full Text] [Related]
11. Kaempferol blocks neutrophil extracellular traps formation and reduces tumour metastasis by inhibiting ROS-PAD4 pathway.
Zeng J; Xu H; Fan PZ; Xie J; He J; Yu J; Gu X; Zhang CJ
J Cell Mol Med; 2020 Jul; 24(13):7590-7599. PubMed ID: 32427405
[TBL] [Abstract] [Full Text] [Related]
12. NIR-Driven Water Splitting H
Wang Q; Ji Y; Shi J; Wang L
ACS Appl Mater Interfaces; 2020 May; 12(21):23677-23688. PubMed ID: 32380825
[TBL] [Abstract] [Full Text] [Related]
13. Apoptosis Activation in thyroid cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Lu K; Wei W; Hu J; Wen D; Ma B; Liu W; Wang Y; Lu Z
Med Sci Monit; 2020 Apr; 26():e922518. PubMed ID: 32341329
[TBL] [Abstract] [Full Text] [Related]
14. Diallyl trisulfide, a H
Xu S; Pan J; Cheng X; Zheng J; Wang X; Guan H; Yu H; Bao J; Zhang L
Phytother Res; 2020 May; 34(5):1154-1165. PubMed ID: 31984539
[TBL] [Abstract] [Full Text] [Related]
15. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract] [Full Text] [Related]
16. UNC5B-AS1 promoted ovarian cancer progression by regulating the H3K27me on NDRG2 via EZH2.
Wang H; Su H; Tan Y
Cell Biol Int; 2020 Apr; 44(4):1028-1036. PubMed ID: 31903696
[TBL] [Abstract] [Full Text] [Related]
17. 1,25‑Dihydroxyvitamin D3 enhances the susceptibility of anaplastic thyroid cancer cells to adriamycin‑induced apoptosis by increasing the generation of reactive oxygen species.
Zhang T; He L; Sun W; Qin Y; Zhang P; Zhang H
Mol Med Rep; 2019 Sep; 20(3):2641-2648. PubMed ID: 31524258
[TBL] [Abstract] [Full Text] [Related]
18. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract] [Full Text] [Related]
19. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ
Endocrine; 2019 Jul; 65(1):110-120. PubMed ID: 31102069
[TBL] [Abstract] [Full Text] [Related]
20. Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Wang Z; Dai J; Yan J; Zhang Y; Yin Z
J Cell Mol Med; 2019 Jul; 23(7):4770-4778. PubMed ID: 31087496
[TBL] [Abstract] [Full Text] [Related]
[Next]
